NR 546 Final Exam – Advanced Psychopharmacology
for the PMHNP (2026)
Chamberlain University | 100 Practice Questions with
Answers & Rationales
Question 1. When treating a patient for major depressive disorder, which medication
would the PMHNP consider as a first-line agent?
A. Depakote
B. Selegiline
C. Escitalopram
D. Isocarboxazid
Correct Answer: C
Rationale: SSRIs such as escitalopram are considered first-line pharmacotherapy for
major depressive disorder due to their favorable side effect profile and efficacy .
Depakote is a mood stabilizer used primarily for bipolar disorder. Selegiline and
isocarboxazid are MAOIs, which are typically reserved for treatment-resistant depression
due to dietary restrictions and drug interaction concerns.
Question 2. A patient diagnosed with major depressive disorder reports "always
forgetting to take my pills." Which medication would be most appropriate to consider?
A. Mirtazapine
B. Fluvoxamine
C. Fluoxetine
D. Carbamazepine
Correct Answer: C
,Rationale: Fluoxetine has a long half-life (approximately 4-6 days), making it more
forgiving if a dose is missed. This pharmacokinetic property is beneficial for patients
with adherence difficulties . Mirtazapine and fluvoxamine have shorter half-lives.
Carbamazepine is an anticonvulsant/mood stabilizer, not a first-line antidepressant.
Question 3. A 34-year-old woman with treatment-resistant depression is being
evaluated for pharmacogenomic testing. The PMHNP explains that the CYP2D6 enzyme
is considered a poor metabolizer phenotype. This phenotype is most likely to result in
which clinical consequence when prescribing a CYP2D6 substrate?
A. Rapid drug clearance requiring extended-release formulations
B. Enhanced first-pass metabolism reducing oral bioavailability
C. Subtherapeutic drug levels requiring dose escalation
D. Elevated drug levels increasing the risk of adverse effects
Correct Answer: D
Rationale: A poor metabolizer phenotype for CYP2D6 results in reduced enzyme
activity, leading to slower drug clearance and elevated plasma drug levels, increasing
the risk of adverse effects . Rapid clearance (A) is associated with ultrarapid
metabolizers. Enhanced first-pass metabolism (B) is not a consequence of reduced
CYP2D6 activity, and subtherapeutic levels (C) would not occur with reduced clearance.
Question 4. A 42-year-old man begins taking fluoxetine 20 mg daily for major
depressive disorder. He is also prescribed tramadol for chronic back pain by his primary
care provider. The PMHNP should be most concerned about which potential
interaction?
A. Decreased fluoxetine levels from CYP2D6 inhibition by tramadol
B. Reduced analgesic efficacy of tramadol due to CYP3A4 induction
C. Serotonin syndrome risk due to combined serotonergic effects
D. Increased seizure threshold from combined GABAergic activity
Correct Answer: C
,Rationale: Both fluoxetine (an SSRI) and tramadol (which has serotonin and
norepinephrine reuptake inhibition properties) increase serotonergic tone, creating a
significant risk for serotonin syndrome . Tramadol is not a CYP3A4 inducer (B), nor does
it increase the seizure threshold (it actually lowers it). Fluoxetine levels would not be
decreased by this combination (A).
Question 5. A 28-year-old patient with schizophrenia has been stable on clozapine for 2
years. Routine monitoring reveals a white blood cell count of 2,800/microL and an
absolute neutrophil count of 1,100/microL. The PMHNP understands that clozapine-
induced agranulocytosis is mediated by which mechanism?
A. CYP1A2 metabolic accumulation leading to cellular toxicity
B. Hapten formation triggering complement-mediated neutrophil lysis
C. Direct dose-dependent bone marrow suppression
D. Immune-mediated destruction of neutrophil precursors
Correct Answer: D
Rationale: Clozapine-induced agranulocytosis is an idiosyncratic, immune-mediated
reaction involving antibodies against neutrophil precursors, not a dose-dependent bone
marrow suppressive effect . CYP1A2 metabolism affects clozapine levels (A) but does not
directly cause agranulocytosis. Hapten-mediated complement lysis (B) is not the
established mechanism.
Question 6. A PMHNP is explaining the dopamine hypothesis of schizophrenia to a
nursing student. The student asks which dopaminergic pathway is most directly
associated with the positive symptoms of schizophrenia, such as delusions and
hallucinations.
A. The mesocortical pathway from ventral tegmental area to prefrontal cortex
B. The mesolimbic pathway from ventral tegmental area to nucleus accumbens
C. The nigrostriatal pathway from substantia nigra to striatum
D. The tuberoinfundibular pathway from hypothalamus to pituitary gland
Correct Answer: B
, Rationale: The mesolimbic pathway, projecting from the ventral tegmental area to the
nucleus accumbens, is most directly associated with the positive symptoms of
schizophrenia. Dopamine hyperactivity in this pathway is linked to delusions and
hallucinations . The mesocortical pathway (A) is more associated with negative and
cognitive symptoms. The nigrostriatal pathway (C) is involved in motor control, and the
tuberoinfundibular pathway (D) regulates prolactin release.
Question 7. Which of the following is considered the "pleasure center" of the brain?
A. Corticostriatal thalamocortical loop
B. Mesolimbic dopamine pathway
C. Mesocortical dopamine pathway
D. Nigrostriatal pathway
Correct Answer: B
Rationale: The mesolimbic dopamine pathway, projecting from the ventral tegmental
area to the nucleus accumbens, is the primary brain circuit mediating reward, pleasure,
and reinforcement. This pathway is most implicated in substance use disorders and the
rewarding effects of drugs of abuse .
Question 8. A 45-year-old patient has tried unsuccessfully to quit smoking several times
over the past ten years. Nicotine's actions at which receptors are considered primarily
responsible for its reinforcing effects?
A. Nicotinic acetylcholine receptors in the VTA
B. Muscarinic receptors in the hippocampus
C. Dopamine D2 receptors in the prefrontal cortex
D. Serotonin 5-HT2A receptors in the cortex
Correct Answer: A
Rationale: Nicotine binds to nicotinic acetylcholine receptors in the ventral tegmental
area (VTA), leading to dopamine release in the nucleus accumbens. This dopaminergic
activation is the primary mechanism underlying nicotine's reinforcing and addictive
properties .
for the PMHNP (2026)
Chamberlain University | 100 Practice Questions with
Answers & Rationales
Question 1. When treating a patient for major depressive disorder, which medication
would the PMHNP consider as a first-line agent?
A. Depakote
B. Selegiline
C. Escitalopram
D. Isocarboxazid
Correct Answer: C
Rationale: SSRIs such as escitalopram are considered first-line pharmacotherapy for
major depressive disorder due to their favorable side effect profile and efficacy .
Depakote is a mood stabilizer used primarily for bipolar disorder. Selegiline and
isocarboxazid are MAOIs, which are typically reserved for treatment-resistant depression
due to dietary restrictions and drug interaction concerns.
Question 2. A patient diagnosed with major depressive disorder reports "always
forgetting to take my pills." Which medication would be most appropriate to consider?
A. Mirtazapine
B. Fluvoxamine
C. Fluoxetine
D. Carbamazepine
Correct Answer: C
,Rationale: Fluoxetine has a long half-life (approximately 4-6 days), making it more
forgiving if a dose is missed. This pharmacokinetic property is beneficial for patients
with adherence difficulties . Mirtazapine and fluvoxamine have shorter half-lives.
Carbamazepine is an anticonvulsant/mood stabilizer, not a first-line antidepressant.
Question 3. A 34-year-old woman with treatment-resistant depression is being
evaluated for pharmacogenomic testing. The PMHNP explains that the CYP2D6 enzyme
is considered a poor metabolizer phenotype. This phenotype is most likely to result in
which clinical consequence when prescribing a CYP2D6 substrate?
A. Rapid drug clearance requiring extended-release formulations
B. Enhanced first-pass metabolism reducing oral bioavailability
C. Subtherapeutic drug levels requiring dose escalation
D. Elevated drug levels increasing the risk of adverse effects
Correct Answer: D
Rationale: A poor metabolizer phenotype for CYP2D6 results in reduced enzyme
activity, leading to slower drug clearance and elevated plasma drug levels, increasing
the risk of adverse effects . Rapid clearance (A) is associated with ultrarapid
metabolizers. Enhanced first-pass metabolism (B) is not a consequence of reduced
CYP2D6 activity, and subtherapeutic levels (C) would not occur with reduced clearance.
Question 4. A 42-year-old man begins taking fluoxetine 20 mg daily for major
depressive disorder. He is also prescribed tramadol for chronic back pain by his primary
care provider. The PMHNP should be most concerned about which potential
interaction?
A. Decreased fluoxetine levels from CYP2D6 inhibition by tramadol
B. Reduced analgesic efficacy of tramadol due to CYP3A4 induction
C. Serotonin syndrome risk due to combined serotonergic effects
D. Increased seizure threshold from combined GABAergic activity
Correct Answer: C
,Rationale: Both fluoxetine (an SSRI) and tramadol (which has serotonin and
norepinephrine reuptake inhibition properties) increase serotonergic tone, creating a
significant risk for serotonin syndrome . Tramadol is not a CYP3A4 inducer (B), nor does
it increase the seizure threshold (it actually lowers it). Fluoxetine levels would not be
decreased by this combination (A).
Question 5. A 28-year-old patient with schizophrenia has been stable on clozapine for 2
years. Routine monitoring reveals a white blood cell count of 2,800/microL and an
absolute neutrophil count of 1,100/microL. The PMHNP understands that clozapine-
induced agranulocytosis is mediated by which mechanism?
A. CYP1A2 metabolic accumulation leading to cellular toxicity
B. Hapten formation triggering complement-mediated neutrophil lysis
C. Direct dose-dependent bone marrow suppression
D. Immune-mediated destruction of neutrophil precursors
Correct Answer: D
Rationale: Clozapine-induced agranulocytosis is an idiosyncratic, immune-mediated
reaction involving antibodies against neutrophil precursors, not a dose-dependent bone
marrow suppressive effect . CYP1A2 metabolism affects clozapine levels (A) but does not
directly cause agranulocytosis. Hapten-mediated complement lysis (B) is not the
established mechanism.
Question 6. A PMHNP is explaining the dopamine hypothesis of schizophrenia to a
nursing student. The student asks which dopaminergic pathway is most directly
associated with the positive symptoms of schizophrenia, such as delusions and
hallucinations.
A. The mesocortical pathway from ventral tegmental area to prefrontal cortex
B. The mesolimbic pathway from ventral tegmental area to nucleus accumbens
C. The nigrostriatal pathway from substantia nigra to striatum
D. The tuberoinfundibular pathway from hypothalamus to pituitary gland
Correct Answer: B
, Rationale: The mesolimbic pathway, projecting from the ventral tegmental area to the
nucleus accumbens, is most directly associated with the positive symptoms of
schizophrenia. Dopamine hyperactivity in this pathway is linked to delusions and
hallucinations . The mesocortical pathway (A) is more associated with negative and
cognitive symptoms. The nigrostriatal pathway (C) is involved in motor control, and the
tuberoinfundibular pathway (D) regulates prolactin release.
Question 7. Which of the following is considered the "pleasure center" of the brain?
A. Corticostriatal thalamocortical loop
B. Mesolimbic dopamine pathway
C. Mesocortical dopamine pathway
D. Nigrostriatal pathway
Correct Answer: B
Rationale: The mesolimbic dopamine pathway, projecting from the ventral tegmental
area to the nucleus accumbens, is the primary brain circuit mediating reward, pleasure,
and reinforcement. This pathway is most implicated in substance use disorders and the
rewarding effects of drugs of abuse .
Question 8. A 45-year-old patient has tried unsuccessfully to quit smoking several times
over the past ten years. Nicotine's actions at which receptors are considered primarily
responsible for its reinforcing effects?
A. Nicotinic acetylcholine receptors in the VTA
B. Muscarinic receptors in the hippocampus
C. Dopamine D2 receptors in the prefrontal cortex
D. Serotonin 5-HT2A receptors in the cortex
Correct Answer: A
Rationale: Nicotine binds to nicotinic acetylcholine receptors in the ventral tegmental
area (VTA), leading to dopamine release in the nucleus accumbens. This dopaminergic
activation is the primary mechanism underlying nicotine's reinforcing and addictive
properties .
